Home / Archive / April 2021

April 2021 Volume 17, Issue 4

Volume 17, Issue 4 | April 2021

April 2021

In this Issue

Clinical Trials

Clinical trial transformation

Decentralization accelerates during pandemic, with positive results

JSP191 data positive for cell transplantation

The anti-CD117 antibody is being evaluated as a conditioning agent prior to blood stem cell transplantation

Go with your gut (microbiome)

Study details results on a new method for treating immunotherapy-resistant melanoma patients

Tools & Technology

New support for customized exosomes

Ciloa’s therapeutic protein platform recognized by Sanofi award program

Assembling the kit against COVID-19

Highlights of some of the most recent new R&D tools to curb the pandemic

New promise for drugs against difficult targets

Salipro awarded European patent for direct extraction of membrane proteins and library generation

Diagnostics

Grading non-alcoholic steatohepatitis

Median Technologies teams up with UC San Diego on diagnosing liver fibrosis severity in NASH patients

Brain biomarkers for depression and trauma

Combining machine learning and EEG may have identified an imaging biomarker for better treating PTSD and MDD

Reducing the risk of bacteremia

New biomarkers can predict risk of patients dying from bacteremia

Liquid biopsy for the win in cancer

Twist Bioscience launches NGS methylation detection system for cancer analysis and epigenetic studies

Discovery

Bacteria vs. bacteria

A multi-organization academic team reports on their efforts to combat resistant bacteria with engineered strains

Clues to complexity

Study determines genetic variants of PTSD

Preventing the next pandemic

Two leading scientists call on health agencies to invest in broadly effective vaccines

Three old mice, see how they run

USC’s ‘exercise protein’ doubles running capacity and extends healthy lifespans in older mice

Preclinical

Taking aim at Bcl-xL

Scientists identify a new target for treating age-related eye diseases

Q&A: Engineering the immune system

Engineering and nanotechnology turn immune cells into a cancer drug delivery system

Advances in Fabry disease

Amicus’ engineered hGLA showed greater substrate reduction than wildtype hGLA

Synthetic lethal drugs vs. cancer

Company obtains funding to advance precision oncology

Editor's Focus

COVID-19: Side effects and unintended benefits

The pandemic has not been good to us, but some good things might come out of it

Teaming science while spreading risk—It’s a lottery that works

It takes real strength of character to accept the high risk in pharma and biotech and not be psychologically crippled by it

Commentary

Real world evidence market is growing fast

Applications of RWE-based insights range from drug discovery to supporting regulatory decision-making

Special Reports

Special Report on Neuroscience: Demystifying psychedelics

Researchers add analysis to the mix to move beyond anecdotes